Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022164937 - TREATMENT OF CANCER USING MRNA-MEDIATED VIRUS VACCINATION ANTIGENS DELIVERED BY ATTENUATED BACTERIA

Publication Number WO/2022/164937
Publication Date 04.08.2022
International Application No. PCT/US2022/013949
International Filing Date 26.01.2022
IPC
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 35/76 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
C12N 1/20 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
A61K 39/39 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
CPC
A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • BRADLEY, Christopher [US]/[US]
Inventors
  • BRADLEY, Christopher
  • GRAVEKAMP, Claudia
Agents
  • BORTREE, Timothy, J.
Priority Data
63/141,93326.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF CANCER USING MRNA-MEDIATED VIRUS VACCINATION ANTIGENS DELIVERED BY ATTENUATED BACTERIA
(FR) TRAITEMENT DU CANCER À L'AIDE D'ANTIGÈNES DE VACCINATION PAR VIRUS À MÉDIATION PAR ARNM DÉLIVRÉS PAR DES BACTÉRIES ATTÉNUÉES
Abstract
(EN) Disclosed are methods of treating tumors in a subject including but not limited to reducing the size of a primary tumor, preventing progression of a tumor to metastasis, and reducing the extent of metastasis; comprising administering to the subject an attenuated bacteria that expresses an mRNA-mediated virus vaccination antigen in an amount effective to treat the tumor. Further disclosed are methods of preventing infection of cells in a subject by a virus and/or preventing or reducing in the subject symptoms of a disease caused by the virus; comprising administering to the subject an attenuated bacteria that expresses an mRNA-mediated virus vaccination antigen in an amount effective to protect the subject against the virus and/or its effects. Further disclosed are pharmaceutical compositions, cancer immunotherapy compounds, virus vaccines and therapeutic cancer vaccines comprising an attenuated bacteria that expresses an mRNA-mediated virus vaccination antigen, and methods of developing the same.
(FR) La présente divulgation concerne des méthodes de traitement de tumeurs chez un sujet comprenant, mais sans s'y limiter, la réduction de la taille d'une tumeur primaire, la prévention de la progression d'une tumeur en métastase, et la réduction de l'étendue de la métastase ; comprenant l'administration au sujet d'une bactérie atténuée qui exprime un antigène de vaccination par virus à médiation par ARNm en une quantité efficace pour traiter la tumeur. La présente divulgation concerne en outre des méthodes de prévention d'une infection de cellules chez un sujet par un virus et/ou de prévention ou de réduction des symptômes d'une maladie provoquée par le virus chez le sujet ; comprenant l'administration au sujet d'une bactérie atténuée qui exprime un antigène de vaccination par virus à médiation par ARNm en une quantité efficace pour protéger le sujet contre le virus et/ou ses effets. La présente divulgation concerne en outre des compositions pharmaceutiques, des composés d'immunothérapie anticancéreuse, des vaccins contre le virus et des vaccins thérapeutiques contre le cancer comprenant une bactérie atténuée qui exprime un antigène de vaccination par virus à médiation par ARNm, et des méthodes de développement de ceux-ci.
Latest bibliographic data on file with the International Bureau